Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ADAGIO THERAPEUTICS, INC.

(ADGI)
  Report
Delayed Quote. Delayed Nasdaq - 12/06 04:00:01 pm
32.53 USD   -29.02%
11/30NORTH AMERICAN MORNING BRIEFING : -3-
DJ
11/29Health Care Stocks Hanging On For Narrow Gains Near Monday Close
MT
11/29Health Care Stocks Rising Monday Afternoon
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Health Care Stocks Recovering From Tuesday Selloff

09/29/2021 | 01:20pm EST


ę MT Newswires 2021
All news about ADAGIO THERAPEUTICS, INC.
11/30NORTH AMERICAN MORNING BRIEFING : -3-
DJ
11/29Health Care Stocks Hanging On For Narrow Gains Near Monday Close
MT
11/29Health Care Stocks Rising Monday Afternoon
MT
11/29Top Midday Gainers
MT
11/29--Morgan Stanley Upgrades Adagio Therapeutics to Overweight From Equalweight; Price Tar..
MT
11/29ADAGIO THERAPEUTICS : Reports That None of the Mutations Present in SARS-CoV-2 Variant, Om..
PU
11/29ADAGIO THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
AQ
11/29Top Premarket Gainers
MT
11/29Adagio Therapeutics Stock Surges Pre-Bell on Information Related to ADG20's Effectivene..
MT
11/29Morgan Stanley Upgrades Adagio Therapeutics to Overweight From Equalweight; Price Targe..
MT
More news
Analyst Recommendations on ADAGIO THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -239 M - -
Net cash 2021 35,7 M - -
P/E ratio 2021 -14,6x
Yield 2021 -
Capitalization 3 619 M 3 619 M -
EV / Sales 2021 -
EV / Sales 2022 4,57x
Nbr of Employees -
Free-Float 46,5%
Chart ADAGIO THERAPEUTICS, INC.
Duration : Period :
Adagio Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAGIO THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 32,53 $
Average target price 48,75 $
Spread / Average Target 49,9%
EPS Revisions
Managers and Directors
Tillman U. Gerngross President, Chief Executive Officer & Director
Jane Pritchett V. Henderson Chief Financial Officer
RenÚ Russo Chairman
Laura Walker Chief Scientific Officer
Lynn Connolly Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ADAGIO THERAPEUTICS, INC.0.00%3 619
GILEAD SCIENCES, INC.19.29%87 180
BIONTECH SE310.30%67 585
REGENERON PHARMACEUTICALS29.37%65 347
WUXI APPTEC CO., LTD.21.78%63 017
VERTEX PHARMACEUTICALS-13.24%52 137